This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DuPont (DD) Fortilife NF1000 Membrane Now Available Globally
by Zacks Equity Research
Fortilife NF1000 by DuPont (DD) offers demanding separations in high-pressure industrial wastewater applications.
DuPont's (DD) Tyvek Facility Obtains ISCC PLUS Certification
by Zacks Equity Research
DuPont (DD) gets permission from ISCC PLUS to use sustainable raw materials produced from renewable and recycled sources.
Zacks Industry Outlook Highlights Air Products and Chemicals, DuPont de Nemours and Methanex
by Zacks Equity Research
Air Products and Chemicals, DuPont de Nemours and Methanex are part of the Zacks Industry Outlook article.
3 Diversified Chemical Stocks to Watch Amid Demand Worries
by Anindya Barman
Weak demand in certain markets, destocking and the slowdown in China and Europe pose headwinds for the Zacks Chemicals Diversified industry. APD, DD and MEOH are poised to navigate the industry challenges.
DuPont (DD) Opens New Kalrez Manufacturing Site in Delaware
by Zacks Equity Research
The new Tralee Park Annex facility will significantly increase DuPont (DD) Kalrez perfluoroelastomer components capacity.
DuPont's (DD) Q3 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
DuPont's (DD) earnings top estimates in Q3 amid lower volumes.
Compared to Estimates, DuPont de Nemours (DD) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for DuPont de Nemours (DD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DuPont de Nemours (DD) Tops Q3 Earnings Estimates
by Zacks Equity Research
DuPont de Nemours (DD) delivered earnings and revenue surprises of 9.52% and 2.85%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
DuPont (DD) Gears Up for Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DuPont (DD) is likely to have benefited from firm demand in several industrial markets and its pricing and productivity actions in the third quarter.
DuPont de Nemours (DD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eastman Chemical (EMN) Benefits From Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) gains on cost-management actions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
DuPont (DD) Unveils Low-Cyclics Silicone Soft Skin Adhesive
by Zacks Equity Research
The adhesive is created as part of DuPont's (DD) efforts to broaden its portfolio of solutions to support the expanding medical device market.
US Steel (X), DuPont Launch COASTALUME for Coastal Environment
by Zacks Equity Research
U.S. Steel (X) and DuPont create a maintenance-free roofing solution using GALVALUME and Tedlar PVF film for the first time.
DuPont (DD) Opens Adhesives Manufacturing Facility in China
by Zacks Equity Research
The new plant by DuPont (DD) will manufacture adhesives for transportation customers, notably in lightweighting and fast-growing vehicle electrification applications.
The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours
by Zacks Equity Research
Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours are included in this Analyst Blog.
Top Stock Reports for Intel, Anheuser-Busch & HCA Healthcare
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Intel Corporation (INTC), Anheuser-Busch InBev SA/NV (BUD) and HCA Healthcare, Inc. (HCA).
DuPont (DD) Benefits From Innovation and Spectrum Acquisition
by Zacks Equity Research
While DuPont (DD) faces headwinds from sluggishness in some markets, it benefits from innovation, the Spectrum Plastics acquisition and pricing and productivity actions.
DuPont (DD) Offers Ion Exchange Resin for Green Hydrogen
by Zacks Equity Research
AmberLite P2X110 Ion Exchange Resin by DuPont (DD) represents a first step into the Green Hydrogen market.
DuPont's (DD) Delrin Introduces Breakthrough New Resin
by Zacks Equity Research
The new resin by DuPont's (DD) unit Delrin is based on formulations that have set the bar for high-performance plastic gears.
Why You Should Retain DuPont (DD) Stock in Your Portfolio
by Zacks Equity Research
DuPont (DD) gains on its focus on growth though innovation, the Spectrum Plastics acquisition and pricing and productivity actions amid headwinds from sluggishness in some markets.
DuPont (DD) to Repurchase $2B Stock in New ASR Transaction
by Zacks Equity Research
DuPont (DD) completes a $3.25 billion accelerated share repurchase transaction and announces a new $2 billion ASR transaction.
DuPont (DD) Announces Strategic Collaboration with YMT in Korea
by Zacks Equity Research
The partnership combines DuPont's (DD) knowledge in circuit imaging materials with YMT's local network, allowing them to best serve local customer needs.
DuPont de Nemours (DD) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DuPont de Nemours (DD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DuPont (DD) Gains on Innovation and Spectrum Plastics Buyout
by Zacks Equity Research
DuPont (DD) benefits from pricing and productivity actions, growth though innovation and the Spectrum acquisition amid weaker demand in certain markets.
DuPont (DD) to Divest 80% Stake in Delrin for $1.8 Billion
by Zacks Equity Research
DuPont (DD) will receive roughly $1.25 billion in pre-tax cash proceeds, subject to standard transaction adjustments.